IN8bio (NASDAQ:INAB – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.09, FiscalAI reports.
IN8bio Stock Up 0.9%
Shares of INAB traded up $0.01 during trading on Friday, reaching $0.98. The company’s stock had a trading volume of 36,582 shares, compared to its average volume of 62,575. The company has a fifty day moving average of $1.33 and a two-hundred day moving average of $1.58. IN8bio has a twelve month low of $0.90 and a twelve month high of $2.73. The company has a market cap of $9.64 million, a price-to-earnings ratio of -0.60 and a beta of 0.24.
Wall Street Analysts Forecast Growth
INAB has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of IN8bio in a report on Friday, July 17th. HC Wainwright restated a “buy” rating on shares of IN8bio in a research note on Thursday, June 4th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $4.00.
Institutional Trading of IN8bio
Hedge funds have recently made changes to their positions in the stock. HRT Financial LP bought a new stake in shares of IN8bio in the fourth quarter worth $34,000. Captrust Financial Advisors bought a new position in IN8bio during the 4th quarter valued at $43,000. Citadel Advisors LLC bought a new position in IN8bio during the 3rd quarter valued at $54,000. Two Sigma Investments LP acquired a new position in IN8bio during the 3rd quarter worth $107,000. Finally, Franklin Resources Inc. grew its holdings in IN8bio by 381.6% during the 4th quarter. Franklin Resources Inc. now owns 914,531 shares of the company’s stock worth $2,048,000 after acquiring an additional 724,637 shares in the last quarter. Institutional investors and hedge funds own 92.05% of the company’s stock.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.
Featured Stories
- Five stocks we like better than IN8bio
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for IN8bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IN8bio and related companies with MarketBeat.com's FREE daily email newsletter.
